泰林生物(300813) - 2024 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2024 was ¥80,006,616.11, representing a 1.34% increase compared to ¥78,946,553.19 in the same period last year[4] - Net profit attributable to shareholders decreased by 66.58% to ¥5,873,080.66 from ¥17,575,025.59 year-on-year[4] - Basic earnings per share dropped by 76.19% to ¥0.05 from ¥0.21 in the same period last year[4] - The operating profit for Q1 2024 was CNY 5,839,769.83, down 67.7% from CNY 18,061,319.64 in Q1 2023[16] - The company’s total profit for Q1 2024 was CNY 5,915,782.07, down 67.4% from CNY 18,119,742.81 in Q1 2023[16] - Total revenue from sales of goods and services was CNY 69,307,264.31, slightly down from CNY 70,164,007.52 year-over-year[19] Cash Flow and Financial Position - The net cash flow from operating activities improved by 64.64%, reaching -¥6,296,392.84 compared to -¥17,807,115.09 in the previous year[4] - The company reported a significant increase of 784.97% in cash received from investment activities, totaling ¥176,994,526.02 compared to ¥20,000,000.00 in the previous year[8] - The net cash flow from operating activities was negative CNY 6,296,392.84, an improvement from negative CNY 17,807,115.09 in the previous year[20] - The company recorded cash inflow from investment activities of CNY 176,994,526.02, significantly higher than CNY 20,021,328.30 in the same period last year[20] Assets and Liabilities - Total assets decreased by 3.04% to ¥943,881,120.62 from ¥973,507,907.87 at the end of the previous year[4] - Cash and cash equivalents at the end of Q1 2024 were CNY 381,299,872.13, down 3.99% from CNY 396,982,503.20 at the beginning of the quarter[12] - Accounts receivable decreased to CNY 30,667,162.32, a decline of 15.00% from CNY 36,082,237.96 at the start of the quarter[12] - Total current assets amounted to CNY 610,612,858.58, down 4.40% from CNY 638,750,200.42 at the beginning of the quarter[13] - Total liabilities decreased to CNY 288,045,720.37, a reduction of 10.92% from CNY 323,268,730.54 at the end of the previous quarter[14] - Total equity attributable to shareholders increased to CNY 654,691,034.97, up from CNY 648,762,936.31 at the end of the previous quarter[14] Expenses and Financial Performance - Total operating costs for Q1 2024 were CNY 77,318,177.90, up 19.00% from CNY 64,924,390.99 in the same period last year[15] - Research and development expenses increased to CNY 14,896,419.24, reflecting a rise of 6.80% from CNY 13,945,439.84 in Q1 2023[15] - The company’s financial expenses surged by 122.25% to ¥659,825.50 due to the capitalization of convertible bond interest expenses[8] - The company experienced a decrease in financial expenses, reporting CNY 659,825.50, compared to a loss of CNY 2,965,848.16 in the previous year[16] - The company’s tax expenses for Q1 2024 were CNY 374,577.16, a decrease from CNY 544,717.22 in the same period last year[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,529, with the largest shareholder holding 53.19% of the shares[10] - The company received government subsidies amounting to ¥279,310.38 during the reporting period[7] Other Financial Metrics - The company’s weighted average return on equity decreased to 0.90% from 2.68% in the previous year[4] - Inventory at the end of Q1 2024 was CNY 150,289,218.55, down 6.45% from CNY 160,550,413.98 at the beginning of the quarter[12] - The company reported a net profit margin improvement, although specific figures were not disclosed in the provided content[15]